Anticoagulant activity of the enantiomers of acenocoumarol.

por Meinertz, T, Kasper, W, Kahl, C, Jähnchen, E
Publicado em 1978

Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIH...

por Maschmeyer, G., Carratalà, J., Buchheidt, D., Hamprecht, A., Heussel, C.P., Kahl, C., Lorenz, J., Neumann, S., Rieger, C., Ruhnke, M., Salwender, H., Schmidt-Hieber, M., Azoulay, E.
Publicado no Ann Oncol (2015)

PD-027 BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)

por Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Hielscher, J., Lerch, M., Scheithauer, W., Jagenburg, A., Held, S., Modest, D., Jung, A., Kirchner, T., Heinemann, V.
Publicado no Ann Oncol (2016)

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

por Stintzing, S, Wirapati, P, Lenz, H -J, Neureiter, D, Fischer von Weikersthal, L, Decker, T, Kiani, A, Kaiser, F, Al-Batran, S, Heintges, T, Lerchenmüller, C, Kahl, C, Seipelt, G, Kullmann, F, Moehler, M, Scheithauer, W, Held, S, Modest, D P, Jung, A, Kirchner, T, Aderka, D, Tejpar, S, Heinemann, V
Publicado no Ann Oncol (2019)

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)

por Nast, A., Kopp, I., Augustin, M., Banditt, K. B., Boehncke, W. H., Follmann, M., Friedrich, M., Huber, M., Kahl, C., Klaus, J., Koza, J., Kreiselmaier, I., Mohr, J., Mrowietz, U., Ockenfels, H. M., Orzechowski, H. D., Prinz, J., Reich, K., Rosenbach, T., Rosumeck, S., Schlaeger, M., Schmid-Ott, G., Sebastian, M., Streit, V., Weberschock, T., Rzany, B.
Publicado em 2007